Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Income from Continuing Operations: 2016-2025

Historic Income from Continuing Operations for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Sep 2025 value amounting to -$180.4 million.

  • Ultragenyx Pharmaceutical's Income from Continuing Operations fell 35.12% to -$180.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$581.2 million, marking a year-over-year decrease of 3.97%. This contributed to the annual value of -$570.6 million for FY2024, which is 5.95% up from last year.
  • According to the latest figures from Q3 2025, Ultragenyx Pharmaceutical's Income from Continuing Operations is -$180.4 million, which was down 56.95% from -$115.0 million recorded in Q2 2025.
  • In the past 5 years, Ultragenyx Pharmaceutical's Income from Continuing Operations registered a high of -$73.0 million during Q3 2021, and its lowest value of -$245.1 million during Q3 2022.
  • In the last 3 years, Ultragenyx Pharmaceutical's Income from Continuing Operations had a median value of -$151.1 million in 2025 and averaged -$147.6 million.
  • Per our database at Business Quant, Ultragenyx Pharmaceutical's Income from Continuing Operations tumbled by 583.62% in 2021 and then spiked by 34.87% in 2023.
  • Ultragenyx Pharmaceutical's Income from Continuing Operations (Quarterly) stood at -$124.8 million in 2021, then fell by 24.34% to -$155.2 million in 2022, then grew by 20.60% to -$123.2 million in 2023, then dropped by 9.39% to -$134.8 million in 2024, then plummeted by 35.12% to -$180.4 million in 2025.
  • Its Income from Continuing Operations was -$180.4 million in Q3 2025, compared to -$115.0 million in Q2 2025 and -$151.1 million in Q1 2025.